UBS Group’s Global X China Biotech Innovation ETF CHB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-23
| Closed | -$186 | – | 10383 |
|
|
2023
Q4 | $186 | Sell |
23
-1,235
| -98% | -$9.84K | ﹤0.01% | 8833 |
|
|
2023
Q3 | $9.51K | Buy |
+1,258
| New | +$9.44K | ﹤0.01% | 7135 |
|
|
2023
Q1 | – | Sell |
-1,538
| Closed | -$14.5K | – | 10886 |
|
|
2022
Q4 | $14.5K | Sell |
1,538
-25
| -2% | -$228 | ﹤0.01% | 8068 |
|
|
2022
Q3 | $13K | Buy |
1,563
+1,361
| +674% | +$13.7K | ﹤0.01% | 8095 |
|
|
2022
Q2 | $2K | Buy |
+202
| New | +$2.04K | ﹤0.01% | 9676 |
|
|
2022
Q1 | – | Sell |
-1,749
| Closed | -$25K | – | 11168 |
|
|
2021
Q4 | $25K | Sell |
1,749
-186
| -10% | -$2.85K | ﹤0.01% | 7600 |
|
|
2021
Q3 | $31K | Buy |
1,935
+1,056
| +120% | +$18.2K | ﹤0.01% | 6729 |
|
|
2021
Q2 | $17K | Buy |
+879
| New | +$16K | ﹤0.01% | 7535 |
|
|
2021
Q1 | – | Sell |
-1,205
| Closed | -$20K | – | 9616 |
|
|
2020
Q4 | $20K | Buy |
+1,205
| New | +$18.9K | ﹤0.01% | 6962 |
|
UBS Group's CHB Position: Q1 2024 in Review
UBS Group sold out of Global X China Biotech Innovation ETF (CHB) in Q1 2024, closing a stake of 23 shares — an estimated $186 sold.
UBS Group first reported a position in CHB in Q4 2020 and held it in 9 quarters. The position peaked at $31K in Q3 2021. 0 funds tracked by Wall St. Rank hold CHB as of Q1 2024.
- UBS Group reported no remaining Global X China Biotech Innovation ETF position as of Q1 2024 after selling out during the quarter.
- UBS Group sold 23 Global X China Biotech Innovation ETF shares in Q1 2024, an estimated $186.
- UBS Group first reported a position in Global X China Biotech Innovation ETF in Q4 2020 and held it in 9 quarters.
- UBS Group's Global X China Biotech Innovation ETF position peaked at $31K in Q3 2021.
- 0 funds tracked by Wall St. Rank held Global X China Biotech Innovation ETF as of Q1 2024.
Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.